Browsing Tag
Plaque psoriasis
10 posts
Aging biotech just got a real skin test and Rubedo Life Sciences may have passed the first one
Rubedo Life Sciences posted early RLS-1496 skin trial data. Read why these Phase 1 results could matter for dermatology, aging science, and biotech.
Johnson & Johnson’s icotrokinra demonstrates superiority in plaque psoriasis trials, setting stage for market disruption
New clinical trial data from Johnson & Johnson suggests that icotrokinra results could mark a major shift in…
Sun Pharma reveals new clinical data at the 2024 EADV Congress, showing significant improvements in severe skin conditions
Sun Pharmaceutical Industries Limited has made a significant breakthrough in the treatment of severe dermatological conditions, unveiling new…
Can-Fite submits pediatric plan to FDA for Piclidenoson in psoriasis treatment
Biotech leader Can-Fite BioPharma, known for its advances in oncology, inflammatory, and liver diseases, has taken a significant…
EMA accepts MAA for Dong-A ST’s Stelara biosimilar, DMB-3115
Dong-A ST, the South Korean pharmaceutical company, has received confirmation from the European Medicine Agency (EMA) of the…
Lupin secures Health Canada approval for Enbrel biosimilar – Rymti
Lupin Limited has secured approval from Health Canada for Rymti, the company’s biosimilar to Enbrel (etanercept), an inhibitor…
Zydus Cadila gets FDA approval for Apremilast Tablets
Zydus Cadila said that its subsidiary Zydus Pharmaceuticals (USA) has secured final approval from the US Food and…
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)…
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis.…
Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas
In a significant advancement for biopharmaceuticals, Novartis’ division Sandoz has secured approval from the European Commission (EC) for…